Iterum Therapeutics plc ITRM 深 沪
等待开盘 12-20 09:30:00 美东时间
0.3723
-0.009
-2.26%
华盛通- 最 高0.3918
- 今 开0.3777
- 成交量 19.93万股
- 最 低 0.3704
- 昨 收 0.3809
- 总市值 1489.20万
- 52周最高 2.10
- 市盈率 静 --
- 换手率 0.50%
- 52周最低 0.3622
- 委 比 0.00%
- 总股本 4000.00万
- 历史最高 195.00
- 量 比 0.49
- 振 幅 5.62%
- 历史最低 0.3622
- 每 手 1
- 风险率 0.39%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Iterum Therapeutics Provides Business Update
Iterum Therapeutics plc provided a business update, highlighting recent developments including expanded market access for ORLYNVAH™ through a major PBM agreement, covering over 40 million lives starting in early 2026, and the expansion of its patent estate with a Japanese patent grant for sulopenem etzadroxil, probenecid, and valproic acid combination, projected to expire in March 2041. The company remains optimistic about securing additional pay...
12-17 13:00
Iterum Therapeutics Faces Nasdaq Listing Compliance Challenge
Iterum Therapeutics ( ($ITRM) ) has issued an announcement. On December 11, 202...
12-13 06:34
Iterum Therapeutics shares are trading higher after the company announced it expanded ORLYNVAH access, secured a Medicare Part D milestone and strengthened its patent portfolio.
Iterum Therapeutics shares are trading higher after the company announced it ex...
12-05 22:16
Iterum Therapeutics Provides Business Update
Iterum Therapeutics plc announced business updates, including expanded reimbursement access for ORLYNVAH™ reaching nearly 25% of U.S. insured lives, a signed rebate agreement with a top Medicare Part D Pharmacy Benefits Manager for potential Q1 2026 coverage, and the addition of Cencora as a specialty distributor. The European Patent Office granted a patent for a sulopenem etzadroxil-probenecid bilayer tablet, expiring in December 2039. The compa...
12-05 13:00
Iterum Therapeutics Provides Business Update
<p>Iterum Therapeutics has announced updates on its business, including the stocking of ORLYNVAH™ at McKesson and the FDA clearance of its sulopenem susceptibility disc. ORLYNVAH™ is now available through McKesson's specialty distribution channel, allowing physicians to procure the product directly. The FDA-cleared disc, manufactured by Liofilchem®, is intended for use in microbiology laboratories for susceptibility testing to determine Enterobac...
11-24 13:00
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Olema Pharmaceuticals (NASDAQ:OLMA) stock increased by 137.7% to $20.2...
11-19 01:06
电话会总结 ｜ Iterum Therapeutics (ITRM) Earnings Transcript
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Iterum Therapeutics (ITRM) 2025年第三季度业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - 净产品收入：2025年第三季度实现40万美元，这是公司首次录得产品收入，来源于8月20日开始的Orlynda美国市场销售，包括专业药房的初始库存 **盈利能力：** - GAAP净亏损：2025年第三季度净亏损900万美元，去年同期净亏损610万美元 - Non-GAAP净亏损：2025年第三季度净亏损730万美元，去年同期净亏损480万美元 - 销售成本：第三季度为2万美元，主要由与辉瑞许可
11-15 12:11
Iterum Therapeutics Q3 Adj. EPS $(0.16) Misses $(0.11) Estimate, Sales $390.000K
Iterum Therapeutics (NASDAQ:ITRM) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.11) by 45.45 percent. This is a 33.33 percent increase over losses of $(0.24) per share
11-14 20:01
Earnings Scheduled For November 14, 2025
Companies Reporting Before The Bell • Inhibrx Biosciences (NASDAQ:INBX) is expe...
11-14 19:11
Iterum Therapeutics Q3 Earnings Preview
Iterum Therapeutics (ITRM) is scheduled to announce Q3 earnings results on Friday, November 14th, before market open. The consensus EPS Estimate is -$0.09 (+62.5% Y/Y)Over the last 2 years, ITRM has b...
11-13 23:46
